Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Discovery of (E)-3-(4-(Diethylamino) phenyl)-1-phenyl-2-phenylsulfonyl)prop-2-en-1-one as Novel Cannabinoid Receptor 2 Ligands

Xing, Changrui (2016) Discovery of (E)-3-(4-(Diethylamino) phenyl)-1-phenyl-2-phenylsulfonyl)prop-2-en-1-one as Novel Cannabinoid Receptor 2 Ligands. Master's Thesis, University of Pittsburgh. (Unpublished)

[img] PDF
Submitted Version
Restricted to University of Pittsburgh users only until 12 April 2021.

Download (1MB) | Request a Copy

Abstract

Cannabinoids (CB) are defined as a class of compounds that can act on Cannabinoid receptors 1 or 2 (CB1 or CB2) and affect human physiology. Both CB1 and CB2 receptors belong to the rhodopsin-like family of G-Protein Coupled Receptors (GPCRs). However, CB1 receptor is mainly expressed in the central nervous system, while CB2 receptor is dominantly located in the peripheral nervous system and immune cells. By now, scientists have discovered many CB ligands that have therapeutic potentials, but the limitation of non-selective ligands is the psychiatric side effect mediated by the activation of CB1 receptor. Although CB1 receptor is crucial in analgesic and anti-inflammatory effects, strategies of designing CB2 selective ligands are made by medicinal chemists to avoid undesirable effects in clinic. In this thesis, we discovered novel CB2 lead compounds with new chemical scaffolds; designed and synthesized four series of analogues for the structure-activity relationship (SAR) studies; tested their binding affinity to both CB2 and CB1 receptors; conducted in-vitro functional studies; and evaluated their potentials for therapeutic treatment.
In total, four series of (E)-3-(4-Ethoxy-3-methoxyphenyl)-2-((4-methoxyphenyl) sulfonyl)-1-phenylprop-2-en-1-one have been identified as novel cannabinoid ligands. Physicochemical properties were predicted and docking studies using our CB2 model was conducted. 29 derivatives were then synthesized to conduct SAR studies. The binding affinity and selectivity for cannabinoid receptor CB1 and CB2 were then evaluated. Four compounds showed high CB2 binding affinity (Ki of 10-60 nM) and good selectivity (CB1/CB2 of 20- to 1305 fold). Their off-targets effects were also predicted. Overall, these sulfone derivatives can be used to develop novel therapeutic CB2 ligands.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: University of Pittsburgh ETD
Status: Unpublished
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Xing, Changruichx23@pitt.eduCHX230000-0001-5028-1208
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Committee ChairXie, Xiangqunxix15@pitt.eduXIX15
Committee MemberYang, Pengpey12@pitt.eduPEY12
Committee MemberWang, Lirongliw30@pitt.eduLIW30
Date: 12 April 2016
Date Type: Publication
Defense Date: 25 March 2016
Approval Date: 12 April 2016
Submission Date: 11 April 2016
Access Restriction: 5 year -- Restrict access to University of Pittsburgh for a period of 5 years.
Number of Pages: 76
Institution: University of Pittsburgh
Schools and Programs: School of Pharmacy > Pharmaceutical Sciences
Degree: MS - Master of Science
Thesis Type: Master's Thesis
Refereed: Yes
Uncontrolled Keywords: Cannabinoid, Cannabinoid receptor, CB2 selective ligands, (E)-3-(4-ethoxy-3-methoxyphenyl)-2-((4-methoxyphenyl) sulfonyl)-1-phenylprop-2-en-1-one
Date Deposited: 12 Apr 2016 13:48
Last Modified: 15 Nov 2016 14:32
URI: http://d-scholarship.pitt.edu/id/eprint/27650

Metrics

Monthly Views for the past 3 years

Plum Analytics


Actions (login required)

View Item View Item